Rabbit Recombinant Monoclonal CO8A antibody. Suitable for WB and reacts with Human samples. Cited in 1 publication.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Flow Cyt | WB | IHC-P | ICC/IF | |
---|---|---|---|---|
Human | Not recommended | Tested | Not recommended | Not recommended |
Mouse | Not recommended | Not recommended | Not recommended | Not recommended |
Rat | Not recommended | Not recommended | Not recommended | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/1000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Constituent of the membrane attack complex (MAC) that plays a key role in the innate and adaptive immune response by forming pores in the plasma membrane of target cells. C8A inserts into the target membrane, but does not form pores by itself.
Complement component C8 alpha chain, Complement component 8 subunit alpha, C8A
Rabbit Recombinant Monoclonal CO8A antibody. Suitable for WB and reacts with Human samples. Cited in 1 publication.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
The Complement C8 protein plays an important role in the immune response specifically as a component of the membrane attack complex (MAC). Known also simply as C8 it is composed of three subunits: C8α C8β and C8γ with a combined molecular mass of approximately 151 kDa. C8 is synthesized primarily by liver hepatocytes but its expression occurs in several other tissues such as monocytes and macrophages highlighting its significance in immune surveillance.
The membrane attack complex is a pivotal element of the complement system where Complement C8 serves as a final assembly participant. It collaborates with other proteins such as C5b C6 and C7 to penetrate and lyse target cell membranes protecting the host against pathogenic invaders. C8 forms part of a larger complement cascade which activates sequentially ensuring swift response to microbial threats. This process highlights its relevance in innate immunity.
Several significant biological processes involve Complement C8. The complement system and the coagulation pathway both rely on this protein's function. Within these pathways C8 associates closely with proteins such as C9 in forming the lytic pore of the MAC and C3b which facilitates the opsonization and clearance of pathogens. These collaborative actions support efficient immune defense and maintain homeostatic balance within the bloodstream.
Complement system dysregulation can link to immune complex diseases such as systemic lupus erythematosus (SLE) and paroxysmal nocturnal hemoglobinuria (PNH). In SLE improper complement activation possibly involving Complement C8 may lead to the formation of immune complexes that cause inflammation and tissue damage. In PNH the lack of complement inhibitory proteins results in red blood cell destruction where the unregulated MAC formation involving C8 plays a part in the hemolytic process. Understanding these connections helps unravel the complex roles that Complement C8 has in disease pathogenesis.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Blocking and diluting buffer and concentration: 5% NFDM/TBST.
Exposure time: 3 seconds.
All lanes: Western blot - Anti-Complement C8 antibody [EPR23646-22] (ab273626) at 1/1000 dilution
All lanes: Human plasma at 20 µg
All lanes: VeriBlot for IP secondary antibody(HRP)(VeriBlot for IP Detection Reagent (HRP) ab131366) at 1/1000 dilution
Predicted band size: 65 kDa
Observed band size: 65 kDa
Blocking and diluting buffer and concentration: 5% NFDM/TBST.
The molecular weight observed is consistent with what has been described in the literature (PMID: 23869880).
Low expression: HEK-293 (Database: EBI-Expression Atlas, HPA).
Exposure time: 3 seconds.
All lanes: Western blot - Anti-Complement C8 antibody [EPR23646-22] (ab273626) at 1/1000 dilution
Lane 1: HepG2 (human hepatocellular carcinoma epithelial cell) whole cell lysate at 20 µg
Lane 2: HEK-293 ( human embryonic kidney epithelial cell) whole cell lysate at 20 µg
All lanes: Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution
Predicted band size: 65 kDa
Observed band size: 65 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com